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potential population level impact 
on tuberculosis incidence of using 
an mRnA expression signature 
correlate-of-risk test to target 
tuberculosis preventive therapy
tom Sumner1, thomas J. Scriba  2, Adam penn-nicholson2, Mark Hatherill2 & 
Richard G. White  1
Achieving the WHo end-tuberculosis (tB) targets requires approaches to prevent progression to tB 
among individuals with Mycobacterium tuberculosis (M.tb) infection. Effective preventive therapy 
(PT) exists, but current tests have low specificity for identifying who, among those infected, is at risk 
of developing tB. Using mathematical models, we assessed the potential population-level impact 
on TB incidence of using a new more specific mRNA expression signature (COR) to target PT among 
HiV-uninfected adults in South Africa. We compared the results to the use of the existing interferon-γ 
release assay (IGRA). With annual screening coverage of 30% COR-targeted PT could reduce TB 
incidence in 2035 by 20% (95% CI 15–27). With the same coverage, IGRA-targeted PT could reduce TB 
incidence by 39% (31–48) but would require greater use of PT resulting in a higher number needed to 
treat per TB case averted (COR: 49 (29–77); IGRA: 84 (59–123)). The relative differences between COR 
and iGRA were not sensitive to screening coverage. coR-targeted pt could contribute to reducing 
total TB burden in high incidence countries like South Africa by allowing more efficient targeting of 
treatment. to maximise impact, coR-like tests may be best utilised in the highest burden regions, or 
sub-populations, within these countries.
Achieving the World Health Organisation (WHO) End-Tuberculosis (TB) strategy targets (reducing TB deaths by 
95% and TB cases by 90%)1, and ultimately eliminating the disease, will not be possible without tools to prevent 
progression to TB among individuals with Mycobacterium tuberculosis (M.tb) infection2. Effective regimens for 
preventive therapy exist3,4 but treating the quarter of the global population estimated to be infected with M.tb5 
is unlikely to be feasible, especially given the relatively low lifetime risk of developing disease and the rare, yet 
potential, adverse effects of prophylactic treatment.
Existing tests for M.tb infection, such as the tuberculin skin test (TST) and interferon-γ release assay (IGRA), 
have poor specificity for predicting who will progress to disease. New, more specific tests, which could more accu-
rately identify those individuals at greatest risk of developing TB, and therefore allow better targeted preventive 
therapy, are needed. Several such tests are currently under development6,7 and the WHO have recently released 
a target product profile (TPP) outlining the desired characteristics of such a test8. The TPP identified those with 
increased likelihood of recent exposure (such as household contacts) or those with risk factors for developing 
TB (such as people living with HIV) as the primary target groups for such a test, especially in low-risk settings. 
However, in high incidence settings such tests may have value for screening the general population8.
An 11-gene version of a previously validated blood 16-gene mRNA expression signature9 is currently being 
evaluated in a proof-of-concept study in South Africa (Correlate of Risk (COR) Targeted Intervention Study 
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(CORTIS-01; ClinicalTrials.gov NCT02735590)). This 11-gene version of the COR signature has been shown 
to have a specificity of 84% and sensitivity of 71% for predicting TB up to 1 year before the onset of disease in 
adolescents from South Africa10,11. The CORTIS-01 trial aims to further evaluate the diagnostic performance of 
the COR for identifying prevalent TB disease among adults who have not sought health care, and the prognostic 
performance of the COR for predicting incident TB disease in unselected populations. It also aims to test the 
efficacy of providing preventive therapy to COR-positive HIV-uninfected individuals in reducing TB incidence11.
Mathematical models, simplified representations of real world systems often as a system of differential equa-
tions, are increasingly used to study the spread and control of infectious diseases. In this paper we describe the 
results of a mathematical modelling study conducted to assess the potential population-level impact of COR 
targeted preventive therapy in a high TB incidence country using South Africa as an example. Despite declines in 
recent years, TB remains a major public health problem in South Africa. In 2015, there were an estimated 450,000 
incident cases12 and TB was the leading cause of death due to an infectious disease13. While the majority of cases 
occur in HIV-infected individuals who, along with close contacts of TB cases, are recommended to receive pre-
ventive therapy14–16, there is still a significant burden in the HIV-uninfected adult population with an estimated 
TB incidence of 460/100,000 per year (see Appendix).
Using a dynamic transmission, in which the risk of infection depends on the simulated prevalence of disease, 
we estimate the long-term impact, accounting for both the direct benefit of preventing incident TB in those 
treated and the indirect effect of reducing future transmission, of COR targeted preventive therapy among the 
HIV-uninfected adult population. To assess the potential added benefit of more specific COR-like tests we com-
pare the COR strategy to the use of IGRA to target preventive therapy.
Methods
This paper reports the results of a mathematical modelling study related to the CORTIS-01 trial and does not 
report directly on any experiments using human samples. The CORTIS-01 trial protocol was approved by the 
University of Cape Town and all methods are conducted in accordance with relevant guidelines. All participants 
are over 18 years of age and written informed consent was obtained from all participants.
The model used only considers pulmonary forms of TB and does not include extra-pulmonary disease. 
Notification data reported by the WHO indicates that pulmonary diseases accounts for approximately 90% of all 
TB in South Africa. We assume that this proportion remains unchanged in the future.
preventive therapy strategies. We modelled 2 strategies for the future use of preventive therapy in South 
Africa and compared them to a base case of continuation of current practice in which preventive therapy is 
provided to HIV-infected individuals but is not routinely used in the HIV-uninfected population. In the first 
strategy we assume that HIV-uninfected adults are screened with COR while in the second strategy screening is 
conducted with IGRA. In both cases, those with a positive screening result are evaluated for TB to exclude active 
disease. Those found to have disease are offered treatment for active TB while those without disease are offered 
preventive therapy (isoniazid (INH) and rifapentine (RPT) for 3 months (3HP)).
Modelling of a single round of screening. For each strategy, we first calculated the outcomes from a 
single round of screening in a cohort. The population was divided into those with no history of exposure (sus-
ceptibles, S) those with M.tb-infection but not at risk of developing TB in the following year (L), those who will 
become incident TB cases in the next year (progressors, I) and those with prevalent active TB (P). The strategy is 
illustrated in Fig. 1. Details of parameters are given in Table 1.
We simulated 10,000 cohorts with parameters sampled independently from the distributions specified in 
Table 1. From these outputs we calculated the positive predictive value (PPV) for prevalent and incident TB, the 
number needed to screen and test to diagnose one prevalent case, and the number needed to treat with 3HP to 
avert one TB case (assuming adherence to and efficacy of 3HP as indicated in Table 1).
Dynamic transmission modelling of multiple rounds of screening. We then used an age structured 
dynamic transmission model to simulate the long-term population-level impact of each of the strategies. This 
allows us to capture the indirect effect of preventing incident cases on future M.tb transmission. We also estimated 
the amount of testing, TB treatment and 3HP required in each strategy. The model, which is similar in structure 
to a number of published TB models17,18, is illustrated schematically in Fig. 2. Full details of the model can be 
found in the Appendix. As drug resistance is not the focus of the study, for simplicity we do not include it in the 
model. Although the preventive therapy strategies are targeted at HIV-uninfected adults, the transmission model 
includes the HIV-infected population and children to allow us to assess the impact on the overall TB burden. 
Age-specific HIV incidence and ART coverage are time varying external inputs to the model. The HIV-infected 
population is stratified by CD4 count and time on ART. The risk of developing TB and dying from the disease 
depend on CD4 count and ART status. The baseline model was calibrated to the WHO-estimated TB incidence 
and mortality (rate/100,000), TB notifications, the proportion of incident TB in HIV-infected individuals and 
the proportion of TB in children (<15 years of age) in South Africa using a sampling-importance-resampling 
approach. Further details of the model and the calibration methods are given in the Appendix.
The screening and preventive therapy strategies are modelled as for the single round of screening described 
above (see Fig. 1 and Table 1). In our main analysis we assumed that 30% of the HIV uninfected adult population 
were screened per year. We also modelled lower coverages of 5, 10 and 20% to explore how the results depend on 
coverage. In all cases, screening is assumed to be random.
Those identified as prevalent active TB cases (both true positive and false positive) start treatment with proba-
bility κ (to account for pre-treatment loss to follow up). Among true positive prevalent cases who start treatment, 
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a proportion τ are successfully treated and return to the “M.tb-infected” state in the model. Those who are not 
successfully treated remain as prevalent active TB cases.
Those identified by the tests as potential progressors (both true positive and false positive) start preventive 
therapy with probability κ. Among true positive progressors, 3HP is effective with a probability given by the prod-
uct of the adherence and efficacy. These individuals move to the “post-3HP” state (see below). Those in whom 
3HP is not effective become incident TB cases.
M.tb-infected individuals, who will not progress to TB in the next year, and who successfully complete treat-
ment or 3HP move to the “post-3HP” state (see below). Neither treatment for TB or 3HP is assumed to have an 
effect in “susceptible” individuals (i.e. those with no exposure to M.tb).
In our primary analysis, those in the post-3HP state are assumed to be “cured” of their infection, and therefore 
are not at risk of developing reactivation TB, but can be re-infected and either develop primary TB or return to 
the M.tb-infected state (with the same assumed level of protection against primary disease following reinfection 
as those in the M.tb-infected state). Individuals may receive more than one course of 3HP during the timeframe 
considered. In addition, we assume that treatment for M.tb infection does not change the response to IGRA or 
COR19. To explore the importance of key assumptions around preventive therapy we carried out the following 
scenario-based sensitivity analyses: assuming that individuals are still M.tb-infected following 3HP; only allowing 
for a single course of 3HP in any individual.
The dependence of the model predictions on the input parameters were assessed by calculating partial rank 
correlation coefficients (PRCCs) for each input parameter. We also visually assessed the relationship between 
intermediate model outputs (TB incidence, prevalence of infection, annual risk of infection, proportion of disease 
due to recent transmission, proportion of incident TB in HIV-infected and proportion of TB in children) and the 
model predictions using scatter plots.
Results
Modelling of a single round of screening. Table 2 shows the results of a single round of screening. Using 
IGRA, 75% of prevalent TB cases are correctly diagnosed, while in the COR scenario this increases to 81%. 
Both strategies result in a similar proportion of progressors (approximately 70%) correctly being given 3HP. 
The IGRA strategy involves more testing for TB, treatment of active TB and 3HP compared to the COR strategy. 
Approximately 40% of the population would be tested for active TB and offered 3HP in the IGRA scenario com-
pared to approximately 16% based on COR. As a result, the positive predictive value (PPV) for both provision 
of 3HP and treatment of active TB is higher for COR: approximately 2% of those offered 3HP based on the COR 
Figure 1. Decision tree for the preventive therapy strategy. Individuals who screen positive on COR/
IGRA are evaluated for active TB. Individuals found to have active TB are treated for disease, those found 
not to have active TB are provided 3HP. 3HP prevents progression to disease with a probability given by 
the adherence (Adh3HP) and efficacy (Eff3HP). SPCOR = specificity of COR; SEI,COR = sensitivity of COR for 
progression to TB; SEP,COR = sensitivity of COR for prevalent active TB; SPL,IGRA = specificity of IGRA for 
M.tb infection; SEL,IGRA = sensitivity of IGRA for M.tb infection; SEI,IGRA = sensitivity of IGRA for progression 
to TB; SEP,IGRA = sensitivity of IGRA for prevalent active TB; SPD = specificity of evaluation for active TB; 
SED = sensitivity of evaluation for active TB; FP = false positive; TP = true positive; FN = false negative; 
TN = true negative. Full details of parameter values are given in Table 1.
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would have progressed to TB in the next year compared to less than 1% when using IGRA. Similarly, 79% of those 
treated for active TB based on COR are true prevalent TB cases compared to 59% for IGRA (see Table 2).
As expected, the PPV for 3HP is strongly dependent on the sensitivity and specificity of the tests (COR or 
IGRA) and the incidence of TB disease (see Appendix Fig. A.2). For IGRA, the PPV is also strongly determined 
by the prevalence of infection in the population: at a lower prevalence of infection the PPV of IGRA would 
increase. However, for the sensitivity and specificity assumed here, the prevalence of infection would have to be 
below 12% for the PPV of IGRA to exceed that of the COR (see Appendix Fig. A.3). This finding may have rele-
vance for the use of COR like assays in low incidence settings. Of those incorrectly given 3HP (i.e. they are not 
true progressors) approximately 50% are susceptible and 50% M.tb-infected based on the COR. However, in the 
case of IGRA the majority (approximately 95%) are M.tb-infected and potentially could accrue some long-term 
benefit from preventive therapy (see Appendix Fig. A.1).
Dynamic transmission modelling of multiple rounds of screening. Figure 3 shows the baseline fit 
of the transmission model. The model fits to historical estimates of TB incidence and mortality, reported TB 
notifications and the disaggregation of TB incidence by HIV status. The modelled proportion of TB in children 
<15 years of age is 9·9–15·4%, consistent with the estimates reported by WHO (13·2% (6·4–25·3%), see Appendix 
Fig. A.7). The model predicts that with continuation of current practice, and ongoing scale-up of ART, TB inci-
dence will decline to approximately 372/100,000 (248–432) by 2035.
Figure 4 shows the percentage reduction in TB incidence compared to the baseline for each strategy over time 
assuming 30% coverage. This represents the additional reduction in incidence due to the strategy on top of the 
baseline decline shown in Fig. 3. The impact of a single round of screening (in 2020) is similar across both strat-
egies at approximately 5% (see Table 2). The impact increases over time, reaching 20% (15–27%) by 2035 using 
COR. The long-term impact of IGRA-targeted 3HP is larger, reaching 39% (31–48%) by 2035. In both cases, the 
majority of the impact results from preventing incident cases via preventive therapy and less from identifying and 
treating prevalent TB (see Appendix section A.3.2 for a discussion of this finding).
However, IGRA-based strategies involve far greater volumes of testing and treatment for TB and 3HP as illus-
trated in Fig. 5A–C. Approximately 5.5 million people must be tested for TB and 4.6 million people must be 
treated with 3HP per year using IGRA, compared with approximately 1.8 million tested and 1.5 million given 
3HP if using COR.
Parameter Description
Value
(mean and 95% CI) Source
SEP,COR Sensitivity of COR for prevalent TB
0.91
(0.78–0.97) Darboe et al.
10
SEP,IGRA Sensitivity of IGRA for prevalent TB
0.84
(0.78–0.91) Metcalfe et al.
30
SEI,COR Sensitivity of COR for progression
0.71
(0.57–0.82)
Zak et al.9, Penn-Nicholson et al.31, 
Fiore-Gartland et al.11
SEI,IGRA Sensitivity of IGRA for progression
0.72
(0.58–0.82) Rangaka et al.
32
SPCOR Specificity of COR for progression* 0.84(0.79–0.88)
Penn-Nicholson et al.31, Fiore-Gartland 
et al.11
SEL,IGRA Sensitivity of IGRA for M.tb infection
0.78
(0.73–0.82) Pai et al.
33
SPL,IGRA Specificity of IGRA for M.tb infection
0.96
(0.94–0.98) Pai et al.
33
SED Sensitivity of diagnosis (Xpert)
0.89
(0.81–0.94) Steingart et al.
34
SPD Specificity of diagnosis (Xpert)
0.99
(0.96–1) Steingart et al.
34
Adh3HP
Proportion of those starting 3HP who complete (used 
in NNT calculation) 0.82 (0.61–0.95) Sterling et al.
4, Sandgren et al.35
Eff3HP
Efficacy of 3HP for preventing progression to TB in 
those who complete (used in NNT calculation) 0.6 (0.48–0.7)
Smieja et al.3. Assumes that 3HP is non-
inferior to isoniazid4.
L Proportion of population M.tb infected 0.5(0.2–0.8) Assumption
I Proportion of population who will progress to TB (incidence)
0.0046
(0.0028–0.0064)
Calculated for HIV-uninfected adults 
from WHO incidence estimates (see 
Appendix)
P Proportion of population with prevalent TB 0.0076(0.0046–0.0106)
Calculated for HIV-uninfected adults 
from WHO incidence estimates (see 
Appendix)
Table 1. Parameters used to estimate outputs from a single round of screening. Confidence intervals based 
on ACS/SHIP data were calculated using Wilson score interval. All parameters were assumed to follow beta 
distributions. Shape and scale parameters were estimated from median and 95% CI using the rriskdistributions 
package in R36. The susceptible population, S = 1 − L − I − P. *The specificity of COR is assumed to be 
independent of true infection status.
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Figure 5D shows the number needed to treat (NNT) with 3HP to avert one case of TB. This is calculated as the 
cumulative number given 3HP, divided by the cumulative number of cases averted up to a given time. The NNT 
is much lower for COR-based strategies compared to IGRA after a single round (107 (64–178) vs 300 (211–442)). 
Figure 2. Model structure. Core structure of the transmission model. S = susceptible, L = latently infected, 
IN = smear negative TB, IP = smear positive TB, C = post 3HP. Susceptible individuals are infected at a rate that 
depends on the prevalence of active disease. Following infection, some proportion progress directly to active 
disease (primary progression), the remainder entering the M.tb infected state. Infected individuals may remain 
infected, progress to disease (reactivation) or be re-infected, with some reduced risk of developing primary 
disease due to their prior infection. Individuals with active disease can die of TB, self-cure, or be diagnosed 
and treated for TB (recovery). Dashed arrows indicate the reduction in progression to TB (or treatment of M.tb 
infection) as a result of preventive therapy (3HP). For clarity the age structure, background mortality and HIV 
structure are not shown in the figure.
COR IGRA
SINGLE ROUND OF SCREENING
Tested for TB after screening (target group = prevalent cases, P)
% of total population 16.8 (12.9–21.5) 42.0 (20.2–64.5)
% of target group 91.4 (81.2–97.3) 84.1 (77.7–89.2)
Positive predictive value (PPV) for prevalent TB 4.1 (2.4–6.3) 1.5 (0.8–3.4)
Treated for TB (target group = prevalent cases, P)
% of total population 0.8 (0.5–1.3) 1.0 (0.5–2.4)
% of target group 80.9 (70.4–88.7) 74.5 (66.6–81.4)
Positive predictive value (PPV) for prevalent TB 78.5 (46.0–97.8) 58.7 (21.8–95.0)
Number screened to diagnose one prevalent TB case 163.9 (115.2–275.7) 177.4 (124.3–300.9)
Number tested to diagnose one prevalent TB case 27.7 (17.8–48.0) 74.1 (32.6–145.6)
Given 3HP (target group = progressors, I)
% of total population 16.0 (12.0–20.6) 40.7 (18.8–63.1)
% of target group 69.8 (56.5–81.0) 70.9 (58.5–81.6)
Positive predictive value (PPV) for progression to TB 2.0 (1.1–3.1) 0.8 (0.4–1.8)
Number given 3HP to avert one incident TB case 109.7 (63.3–209.7) 272.4 (114.5–589.0)
TRANSMISSION MODEL
% Reduction in TB incidence
2020 5.1 (3.5–7.2) 5.6 (3.9–7.7)
2035 20.4 (15.2–26.9) 38.8 (31.2–48.0)
Cumulative cases averted (thousands)
During 2020 13 (8–20) 14 (9–22)
2020 to 2035 490 (318–767) 839 (541–1296)
“Resources” used (yearly average 2020 to 2035)
Tested for TB (millions) 1.8 (1.3–2.4) 5.5 (4.1–6.4)
Treated for TB (thousands) 12.6 (8.8–18.2) 19.6 (13.8–26.6)
Given 3HP (millions) 1.5 (1.1–1.9) 4.6 (3.4–5.3)
Table 2. Model results.
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These are consistent with the values calculated in the simple model of a single round of screening (see Table 2). 
By 2035 the cumulative NNT for IGRA falls to 84 (59–123) but is still higher than that of COR-based strategies 
(NNT = 49 (29–77)).
For comparison, we also used the transmission model to estimate the potential impact of a test with the opti-
mal characteristics defined in the WHO TPP8. Assuming a sensitivity and specificity of 90% we found a similar 
impact to that achieved with COR (6.1% (4.2–8.3%) after a single round of screening; 19.3% (14.4–25.4%) by 
2035). However, due to the more specific targeting of preventive therapy to those at short term risk of progression 
the cumulative NNT for the optimal TPP test was lower at 30 (19–46).
As expected, the reduction in incidence and the number of cases averted are lower at lower screening coverage 
for both COR and IGRA. In contrast the NNT increases slightly as coverage increases; the larger impact achieved 
with higher coverage means that the prevalence of TB is lower and hence the NNT is higher. Importantly, the rel-
ative difference between the COR and IGRA strategies is largely independent of screening coverage. In 2020 the 
NNT for IGRA is 2.8 times that for COR for all coverages considered. The cumulative NNT by 2035 using IGRA is 
1.5 times that of COR at 5% coverage rising to 1.7 times that of COR at 30% coverage. Full details of these results 
can be found in Appendix Table A.9.
The probabilistic sensitivity analysis (Appendix Fig. A.8) suggests that, for the ranges of parameters consid-
ered here, the impact is most strongly determined by the adherence to, and efficacy of, 3HP. The impact is also 
positively correlated with the annual risk of infection suggesting that the impact of COR may be increased in 
settings with higher levels of ongoing transmission (Fig. A.9). For further details, see the Appendix.
The results of the scenario analysis are shown in Appendix Figs A.11–A.15. The predicted impact of all strate-
gies is sensitive to both the assumed effect of 3HP on infection status (cure vs no cure) and the number of courses 
of 3HP an individual can receive (multiple vs single). Allowing only a single course of 3HP per individual reduces 
the impact of all strategies, however the long-term impact of using IGRA still exceeds that of using COR. Under 
the ‘no-cure’ assumption, the impact of all strategies is approximately the same. When these assumptions are 
combined (no cure, single course of 3HP) the predicted impact of IGRA-targeted 3HP is lower than that of a 
COR-based strategy (Fig. A.11). Only allowing a single round of 3HP also results in a drop in the number of doses 
of 3HP required per year; this drop is greatest in the IGRA-based strategy, resulting in comparable levels of 3HP 
in all strategies by 2035 (see Fig. A.14). However, given the corresponding reduction in predicted impact, the 
NNT with 3HP to avert one TB case remains higher for IGRA (compared to COR) for all combinations of these 
assumptions (see Fig. A.15).
Figure 3. Baseline fit of the model. Black lines show median (dashed) and range (solid lines) of WHO estimates 
of TB incidence and mortality and reported notifications. Shaded areas show 95% confidence interval of the 
model outputs.
7Scientific RepoRtS |         (2019) 9:11126  | https://doi.org/10.1038/s41598-019-47645-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 4. Impact of targeted 3HP. Percentage reduction in TB incidence rate compared to baseline (y-axis) as a 
function of year (x-axis). Shading indicates the strategy. Boxes show the median and interquartile range (IQR). 
Whiskers show the largest values (or 1.5 IQR). Dots indicates outliers.
Figure 5. Resources used and number needed to treat. (A) Number tested for TB (top left); (B) number 
diagnosed and started on TB treatment (top right); (C) number given 3HP (bottom left) and (D) number 
needed to treat with 3HP per case averted (cumulative to year indicated). Shading indicates strategy. Boxes 
show the median and interquartile range (IQR). Whiskers show the largest values (or 1.5 IQR). Dots indicates 
outliers.
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We also considered the impact of the strategies in the absence of 3HP, i.e. what is the impact of COR or IGRA 
as a test for identifying prevalent TB. These results are shown in the Appendix (Table A.10). For all strategies, 
the impact of identifying prevalent cases is predicted to be relatively small (~3.5%) and a minority of the over-
all impact when PT is included. However, it should be noted that this finding is probably dependent on our 
assumptions that all prevalent cases have the same probability of being diagnosed and that infectiousness is 
assumed to be constant throughout the entire duration of disease. If the prevalent cases identified by COR (or 
IGRA) are those who are at the early stages of subclinical or asymptomatic disease and/or those who would not 
be identified via current screening approaches, the impact could be greater. In contrast, if the cases identified by 
COR would then not be correctly diagnosed using the current South African algorithm (Xpert) the impact could 
be reduced. While previous modelling has shown that these factors will influence the potential impact of a new 
diagnostic20 we currently do not have sufficient data to inform the model and have chosen to use the simplest 
possible approach here
Discussion
These results suggest that COR-targeted preventive therapy in HIV-uninfected adults could make an important 
contribution to reducing the TB burden in high incidence countries such as South Africa, with estimated reduc-
tions in incidence of 20% (15–27%) over 15 years. While the model suggests that IGRA-targeted 3HP could result 
in greater reductions in incidence (39% (31–48%)) over the same period, the number of people who would be 
treated with 3HP per year is significantly higher (approximately 4.6 million for IGRA vs 1.5 million for COR). 
When calculated over the time-period considered, the NNT to avert one TB case using IGRA is 1.7 times that for 
COR (84 (59–123) vs 49 (29–77)).
The recently released TPP for tests to predict progression of TB indicated that those with increased likelihood 
of recent exposure or risk factors for progression (such as household contacts or HIV-infected people) should be 
the primary target groups for testing. Our results suggest that in high incidence settings such as South Africa, the 
use of such tests in the general population may have potential. While the estimated PPV of COR targeted 3HP is 
relatively low at around 2%, it is approximately double that for IGRA. To put these values in context, it is useful 
to compare to the PPV among high-risk sub-populations recommended to receive preventive therapy in South 
Africa. For example, WHO and national guidelines suggest that all HIV-infected individuals, irrespective of ART 
status, should receive preventive therapy14,15. In 2015 there were an estimated 258,000 incident TB cases among 
the estimated 7 million HIV-infected individuals in South Africa: an incidence, and hence PPV of preventive 
therapy, of approximately 3·7%21,22.
However, the resources required to screen 30% of the population per year and provide preventive therapy to 
approximately 1.5 million people are likely to be prohibitive. As such, the use of tests such as the COR to screen 
the general population may be best focussed on the highest incidence districts to maximise impact. Such tests 
may also provide additional benefit among those already recommended to receive preventive therapy, including 
HIV-infected individuals and household contacts of TB cases, by identifying those at most immediate risk of 
progression to disease.
Sensitivity analysis suggests that the long-term impact of 3HP, especially in the IGRA strategy, is depend-
ent on the assumption that 3HP “cures” M.tb infection. Our previous analysis of preventive therapy trials in 
HIV-infected populations has suggested a potential lack of “cure” in this group23,24 but it is likely that this is not 
the case in HIV-uninfected people.
As with any model, we have made several simplifying assumptions which may affect the conclusions. Uptake 
and completion of preventive therapy among HIV-infected individuals has been challenging in South Africa25, 
and similar challenges are likely to be experienced in targeted use of 3HP among HIV-uninfected populations. We 
assumed uptake of 3HP following a positive COR or IGRA would be the same as initiation of treatment among 
those diagnosed with active TB which may overestimate the potential impact. Similarly, our assumed values of 
adherence may overestimate what may be observed in programmatic use. We have not included uncertainty in 
future projections of HIV incidence in South Africa. The impact of a strategy targeted at HIV-uninfected adults 
will be affected by the future HIV dynamics. We did not include drug resistance in our model as it was not the 
primary focus of this research. However, approximately 3.5% of TB cases in South Africa are estimated to have 
multi-drug resistant or rifampicin-resistant forms of TB21. This would reduce the overall impact predicted here, 
assuming 3HP is ineffective in preventing progression to drug resistant TB, but should not significantly affect 
the relative difference between COR and IGRA based strategies. There are also concerns that population-level 
preventive therapy may lead to increased drug resistance. However, previous studies have found no significant 
association between isoniazid preventive therapy (IPT) and development of drug resistance26 and modelling has 
suggested that the timescales over which community wide IPT could drive increases in resistance are longer than 
those considered here27.
Based on available data28,29, we have assumed that 3HP does not affect IGRA or COR status and as such those 
who have received effective 3HP will be identified as potential recipients if subsequently screened. If this is not the 
case, this is likely to result in an overestimate of the amount of 3HP required in the IGRA strategies and hence may 
overestimate the long-term NNT for this strategy. We also assumed that COR false positives are equally distributed 
between M.tb-infected and -uninfected individuals which will similarly inflate the NNT estimates for COR. Results 
from the CORTIS-01 study will provide estimates for these variables and reveal the relevance of these assumptions.
conclusion
Targeting 3HP based on a COR-like test could have an important impact on TB incidence and, in HIV-uninfected 
individuals, is likely to be more efficient than using existing tests for M.tb infection such as IGRA. In low-income 
countries, the need to screen and treat large populations may be prohibitive and such tests may be best utilised in 
the highest burden regions within these countries.
9Scientific RepoRtS |         (2019) 9:11126  | https://doi.org/10.1038/s41598-019-47645-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
References
 1. World Health Organisation. The End TB Strategy. Geneva, Switzerland: World Health Organisation (2015).
 2. Dye, C, Glaziou, P., Floyd, K. & Raviglione, M. Prospects for tuberculosis elimination. Annu Rev Public Health. 34, 271–86. Epub 
2012/12/19. PubMed PMID: 23244049, https://doi.org/10.1146/annurev-publhealth-031912-114431 (2013).
 3. Smieja, M. J., Marchetti, C. A., Cook, D. J. & Smaill, F. M. Isoniazid for preventing tuberculosis in non-HIV infected persons 
(Review). The Cochrane Library. 2 (2005).
 4. Sterling, T. et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. NEJM. 365(23) (2011).
 5. Houben, R. M. & Dodd, P. J. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. 
PLoS Med. 13(10), e1002152, https://doi.org/10.1371/journal.pmed.1002152. PubMed PMID: 27780211, PubMed Central PMCID: 
PMC5079585 (2016).
 6. Petruccioli, E et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J. 48(6), 
1751–63, https://doi.org/10.1183/13993003.01012-2016. PubMed PMID: 27836953 (2016).
 7. Suliman, S. et al. Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis. Am J Respir Crit Care Med., https://
doi.org/10.1164/rccm.201711-2340OC PubMed PMID: 29624071 (2018).
 8. World Health Organisation. Consensus meeting report: development of a Target Product Profile (TPP) and a framework for 
evaluation for a test for predicting progression from tuberculosis infection to active disease. Geneva, Switzerland (2017).
 9. Zak, D. E. et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 387(10035), 2312–22. 
PubMed PMID: 27017310, PubMed Central PMCID: PMC5392204, https://doi.org/10.1016/S0140-6736(15)01316-1 (2016).
 10. Darboe, F. et al. Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral 
blood mononuclear cells. Tuberculosis. 108, 124–6, https://doi.org/10.1016/j.tube.2017.11.001. PubMed PMID: 29523312 (2018).
 11. Fiore-Gartland, A et al. Considerations for biomarker-targeted intervention strategies for TB prevention. Tuberculosis. In press, 
https://doi.org/10.1016/j.tube.2017.11.009 (2017).
 12. World Health Organisation. Global Tuberculosis Report Geneva2018 Available from, https://www.who.int/tb/publications/global_
report/en/ [cited 2018 20th September].
 13. Statistics South Africa. Mortality and causes of death in South Africa: Findings from death notification, Pretoria: Statistics South 
Africa, 2018 [cited 2018 3rd April]. Available from, http://www.statssa.gov.za/?page_id=1854&PPN=P0309.3&SCH=7308 (2016).
 14. World Health Organisation. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living 
with HIV in resource-constrained settings. Geneva, Switzerland (2011).
 15. Department of Health South Africa, South African National AIDS Council. South Africa’s National Strategic Plan for HIV, TB and 
STIs 2017–2022 Pretoria, South Africa2017 Available from, http://sanac.org.za/wp-content/uploads/2017/05/NSP_FullDocument_
FINAL.pdf [cited 2017 15th September].
 16. World Health Organisation. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 
Geneva (2018).
 17. Houben, R. M. et al. TIME Impact - a new user-friendly tuberculosis (TB) model to inform TB policy decisions. BMC Med. 14, 
PubMed PMID: 27012808, PubMed Central PMCID: PMC4806495, https://doi.org/10.1186/s12916-016-0608-4 (2016).
 18. Menzies, N. A., Cohen, T., Lin, H. H., Murray, M & Salomon, J. A. Population health impact and cost-effectiveness of tuberculosis 
diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med. 9(11), e1001347. Epub 2012/11/28 
PubMed PMID: 23185139, PubMed Central PMCID: PMC3502465, https://doi.org/10.1371/journal.pmed.1001347 (2012).
 19. Johnson, J. L. et al. Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with 
positive tuberculin skin test results in a high TB incidence area: a controlled study. Chest. 145(3), 612–7 PubMed PMID: 24135768, 
PubMed Central PMCID: PMC3941252, https://doi.org/10.1378/chest.13-1232 (2014).
 20. Arinaminpathy, N. & Dowdy, D. Understanding the incremental value of novel diagnostic tests for tuberculosis. Nature. 528(7580), 
S60–7 PubMed PMID: 26633767, https://doi.org/10.1038/nature16045 (2015).
 21. World Health Organisation. WHO TB Burden Estimates Geneva2016 Available from, https://extranet.who.int/tme/generateCSV.
asp?ds=estimates [cited 2017 17th September].
 22. HIV estimates with uncertianty bounds 1990–2016 [Internet]. Available from, http://www.unaids.org/en/resources/
documents/2017/HIV_estimates_with_uncertainty_bounds_1990-2016 (2016).
 23. Houben, R. M., Sumner, T., Grant, A. D. & White, R. G. Ability of preventive therapy to cure latent Mycobacterium tuberculosis 
infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci USA 111(14), 5325–30. PubMed PMID: 24706842, 
PubMed Central PMCID: PMC3986199, https://doi.org/10.1073/pnas.1317660111 (2014).
 24. Sumner, T. et al. Post-Treatment Effect of Isoniazid Preventive Therapy on Tuberculosis Incidence in Hiv-Infected Individuals on 
Antiretroviral Therapy. AIDS. ePub (2016).
 25. Churchyard, G., Chaisson, R. E., Maartens, G. & Getahun, H. Tuberculosis preventive therapy: an underutilised strategy to reduce 
individual risk of TB and contribute to TB control. S Afr Med J. 104 (2014).
 26. Balcells, M. E., Thomas, S. L., Godfrey-Faussett, P. & Grant, A. D. Isoniazid preventive therapy and risk for resistant tuberculosis. 
Emerg Infect Dis. 12(5), 744–51. PubMed PMID: 16704830, PubMed Central PMCID: PMC3374455, https://doi.org/10.3201/
eid1205.050681 (2006).
 27. Mills, H. L., Cohen, T. & Colijn, C. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based 
analysis. Sci Transl Med. 5(180), 180ra49. PubMed PMID: 23576815, PubMed Central PMCID: PMC3714172, https://doi.
org/10.1126/scitranslmed.3005260 (2013).
 28. Johnson, J. L. et al. Effect of Isoniazid Therapy for Latent TB Infection on QuantiFERON-TB Gold In-Tube Responses in Adults 
With Positive Tuberculin Skin Test Results in a High TB Incidence Area. Chest. 145(3), 612–7. PubMed PMID: 27845635, https://
doi.org/10.1378/chest.13-1232 (2014).
 29. Lee, S. W., Lee, S. H. & Yim, J. J. Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. 
Infection. 40(4), 431–5. PubMed PMID: 22585454, https://doi.org/10.1007/s15010-012-0265-2 (2012).
 30. Metcalfe, J. Z. et al. Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-
income countries: systematic review and meta-analysis. J Infect Dis. 204, Suppl 4, S1120–9 PubMed PMID: 21996694, PubMed 
Central PMCID: PMC3192542, https://doi.org/10.1093/infdis/jir410 (2011).
 31. Penn-Nicholson, A., Scriba, T. J., Hatherill, M., White, R. G. & Sumner, T. A novel blood test for tuberculosis prevention and 
treatment. S Afr Med J. 107(1), 4–5 PubMed PMID: 28112082, https://doi.org/10.7196/SAMJ.2016.v107.i1.12230 (2016).
 32. Rangaka, M. X. et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and 
meta-analysis. Lancet Infect Dis. 12(1), 45–55 PubMed PMID: 21846592, PubMed Central PMCID: PMC3568693, https://doi.
org/10.1016/S1473-3099(11)70210-9 (2012).
 33. Pai, M., Zwerling, A. & Menzies, D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an 
update. Ann Intern Med. 149(3) (2008).
 34. Steingart, K. R. et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database 
Syst Rev. 1, CD009593. Epub 2013/02/27. PubMed PMID: 23440842, https://doi.org/10.1002/14651858.CD009593.pub2 (2013).
 35. Sandgren, A. et al. Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis. 
16, 204 PubMed PMID: 27184748, PubMed Central PMCID: PMC4869320, https://doi.org/10.1186/s12879-016-1550-y (2016).
 36. Belgorodski, N., Greiner, M., Tolksdorf, K. & Katharina, S. Rrisk distributions: Fitting Distributions to Given Data or Known 
Quantiles (2017).
1 0Scientific RepoRtS |         (2019) 9:11126  | https://doi.org/10.1038/s41598-019-47645-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
Acknowledgements
This research was carried out with support from the Bill and Melinda Gates Foundation (OPP1137034). The 
funder had no role in the study design, analysis or writing of the manuscript. The corresponding author (T.S.) had 
final responsibility for the decision to submit for publication.
Author contributions
T.Su., M.H. and R.W. conceived the study. A.P.N. and T.Sc. contributed to the design of the study and provided 
data. T.Su. conducted the modelling analysis and drafted the manuscript. All authors contributed to revision of 
and approved the final manuscript.
Additional information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-47645-z.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
